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ABSTRACT  
A simple, sensitive and specific high-performance liquid chromatography method for the 
quantification of bisnaphthalimidopropyldiaminooctane (BNIPDaoct), a potent anti-
Leishmania compound, incorporated into poly(d,l-lactide-co-glycolic acid) (PLGA) 
nanoparticles was developed and validated toward bioanalysis application. Biological tissue 
extracts were injected into a reversed-phase monolithic column coupled to a fluorimetric 
detector (_exc = 234 nm, _em = 394 nm), using isocratic elution with aqueous buffer (acetic 
acid/acetate 0.10 M, pH 4.5, 0.010 M octanesulfonic acid) and acetonitrile, 60:40 (v/v) at a 
flow rate of 1.5 mL min−1. The run time was 6 min, with a BNIPDaoct retention time of 3.3 
min.  
Calibration curves were linear for BNIPDaoct concentrations ranging from 0.002 to 0.100 
_M. Matrix effects were observed and calibration curves were performed using the different 
organ (spleen, liver, kidney, heart and lung) extracts. The method was found to be specific, 
accurate (97.3–106.8% of nominal values) and precise for intra-day (RSD < 1.9%) and inter-
day assays (RSD < 7.2%) in all matrices. Stability studies showed that BNIPDaoct was 
stable in all matrices after standing for 24 h at room temperature 20 ◦C) or in the 
autosampler, and after three freeze–thaw cycles. Mean recoveries of BNIPDaoct spiked in 
mice organs were >88.4%. The LOD and LOQ for biological matrices were ≤0.8 and ≤1.8 
nM, respectively, corresponding to values ≤4 and ≤9 nmol g−1 in mice organs. The method 
developed was successfully applied to biodistribution assessment. 
INTRODUCTION  
Naphthalimides and bisnaphthalimides are cytotoxic DNAintercalating compounds, with well-
established activity against several cancers [1]. Bisnaphthalimidopropyl derivatives (BNIPs) 
linked to natural polyamines were designed and synthesized to exhibit good cytotoxicity 
against cancer cells and parasites [2–7]. In particular, bisnaphthalimidopropyldiaminooctane 
(BNIPDaoct, Fig. 1) was shown to exert promising activity against certain cancer cells 
(pancreas, breast and leukaemia) and Leishmania infantum protozoa, eliciting cell death by 
apoptosis with DNA damage [4, 8, 9]. However the lack of aqueous solubility and some toxic 
effects to normal cell at higher doses has made BNIPDaoct in vivo testing difficult and highly 
limited [4]. To overcome these problems, BNIPDaoct was incorporated into polymeric 
nanoparticles of poly(lactic-coglycolic) acid (PLGA), a biodegradable and biocompatible 
polymer approved by Food Drug Administration for therapeutic applications. By applying 
such a drug delivery system one can reduce compound cytotoxic activity side effects, 
increase their aqueous solubility properties and alter compound pharmacokinetics profile 
[10]. In a previous report, it was demonstrated that PLGA nanoparticles provided controlled 
and effective delivery of BNIPDaoct for treatment of visceral leishmaniasis caused by 
Leishmania infantum protozoa [11]. In this respect it has emerged a need for rapid, sensitive 
and reliable analytical method that can be used to accurately quantify BNIPDaoct in 
biological samples.  
Concerning the analytical determination of bisnaphthalimides, reports are scarce. A 
validated method for determination of bisnafide in human plasma by HPLC with UV 
detection has been described, requiring extensive sample treatment, involving removal of 
sample proteins, pH adjustment, extraction to ethyl ether followed by back-extraction to 
phosphoric acid aqueous solution [12]. In fact, fluorescent properties of bisnaphthalimides 
 Version: Postprint (identical content as published paper) This is a self-archived document from i3S – Instituto de 
Investigação e Inovação em Saúde in the University of Porto Open Repository For Open Access to more of our 
publications, please visit http://repositorio-aberto.up.pt/  
 
A
0
1
/0
0
 
[13, 14] have been applied for monitoring their binding to biomolecules [15], but their 
application in validated analytical methods have not been described yet.  
In this context, HPLC coupled to fluorometric detection is a suitable tool to bioanalysis of 
nanoparticles loaded with bioactive compounds. In fact, C18 monolithic columns, consisting 
of microand mesopores [16,17], have been shown as suitable alternatives for bioanalysis 
[18,19], fostering minimal sample treatment. Hence, the objective of the present work was 
the development and validation of HPLC method based on monolithic column for 
determination of BNIPDaoct in biological samples, targeting the evaluation of its 
biodistribution as free compound or loaded in nanoparticles. 
EXPERIMENTAL 
Chemicals. Sodium acetate and octanesulfonic acid were purchased from Sigma–Aldrich 
(St. Louis, MO, USA). Acetonitrile (LiChrosolv HPLC grade), dimethyl sulfoxide (DMSO) and 
acetic acid were obtained from Merck (Darmstadt, Germany). Water from Arium water 
purification system (resistivity > 18 M_ cm, Sartorius, Göttingen, Germany) was used for the 
preparation of solutions. PLGA (lactide:glycolide [65:35], molecular weight: 40,000–75,000 
Da) and poly(vinyl alcohol) (PVA; 87–89% hydrolyzed, molecular weight: 13,000–23,000 Da) 
were acquired from Sigma–Aldrich. BNIPDaoct (containing 2HBr, molecular weight of 780.5 
Da), represented in Fig. S1, was synthesized as described previously [4]. 
Preparation and characterization of PLGA nanoparticles containing BNIPDaoct. The 
biodegradable and biocompatible PLGA was used for the production of the nanoparticles by 
a nanoprecipitation method described in detail elsewhere [11]. Briefly, the polymer was 
dissolved in acetone at ∼10 mg mL−1 to form the diffusing phase. BNIPDaoct in DMSO was 
then added to reach 10% drug loading (w/w). This phase (c.a. 1 mL) was added to the PVA 
1% (w/v) dispersing phase (10–15 mL) and the organic solvent was evaporated overnight, at 
room temperature. The formed nanoparticles were then recovered and washed by 
centrifugation, resuspended in phosphate buffered saline (PBS) at pH 7.4. Unloaded PLGA 
nanoparticles were also prepared, using the same procedure without the addition of 
BNIPDaoct. Particle size and distribution (polydispersity index, PI) were determined by 
dynamic light scattering (DLS), using a Zetasizer Nano ZS laser scattering device (Malvern 
Instruments Ltd., Malvern, UK) as described elsewhere [11]. 
Chromatographic analysis: Equipment and analytical conditions. Samples were 
injected (20 _L) into a reversed-phase monolithic column (Chromolith RP-18e, 100 mm °ø 
4.6 mm i.d., Merck), connected to a Jasco (Easton, USA) HPLC system (pump PU-2089, 
autosampler AS-2057 and LC-Net II/ADC controller) coupled to a fluorimetric detector 
(Jasco FP-2020, _exc = 234 nm, _em = 394 nm). The chromatographic separation was 
achieved by isocratic mode using a mobile phase consisting of aqueous buffer (acetic 
acid/acetate 0.10 M, pH 4.5, 0.010 M octanesulfonic acid)- acetonitrile (60:40, v/v) at a flow 
rate of 1.5 mL min−1. Mobile phase was filtered through a 0.22 _m Millipore GVWP filter. 
Prior to use, the mobile phase was degassed in an ultrasonic bath for 15 min. 
Determinations were performed at room temperature (20 °æ 2 ◦C). 
Chromatographic analysis: Preparation of stock and standard solutions. Stock 
solutions of BNIPDaoct were prepared daily in mobile phase at 20 _M, followed by 
intermediate dilution to 1 _M. Working standards were prepared from 1 _M intermediate 
stock solution, ranging from 2 to 100 nM. QC samples at three diferente levels (low, middle 
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and high) were prepared (6, 20 and 100 nM) in mobile phase from the intermediate stock 
solution. 
Chromatographic analysis:  Preparation of biological matrices samples. Firstly, 
methanol was added to each organ at 1:2 (w/v, g/mL) for kidney, liver, and lung or at 1:5 
(w/v, g/mL) for heart and spleen, following homogenization using a high-intensity IKA ultra-
turrax. Next, the homogenates were dried under N2 and then they were reconstituted using 
mobile phase (1:5, w/v, g/mL). This mixture was vigorously vortexed for 30 s, followed by 
sonication during 1 min, and then vortexed again for 30 s. The extract obtained was filtered 
(PVDF, 0.22 _M) and analyzed for BNIPDaoct content by HPLC. QC samples were also 
prepared using the extract, as described in Section 2.3.2. 
Six-week-old male BALB/c mice were used (Charles River, Barcelona, Spain). Animals were 
housed five per cage for acclimatization one week before the experiments at the animal 
resource facilities of the IBMC (Porto, Portugal). All experiments were approved by and 
conducted in accordance with the IBMC/INEB Animal Ethics Committee and the Portuguese 
Veterinary Director General guidelines. Formulations containing BNIPDaoct in solution or 
nanoencapsulated (165 _M) were administered intravenous via the lateral tail vein (1.0 mg 
kg−1) to each group of four healthy male BALB/c mice. The animals were sacrificed 1 h after 
BNIPDaoct injection with lethal dose of anaesthesia. The organs were collected and 
preserved in ice during all the procedure. The concentration of BNIPDaoct in the biological 
matrices (spleen, heart, liver, lungs, and kidneys) was determined by processing the 
samples as described above, with further assessment of BNIPDaoct content by the 
developed and validated HPLC method. 
Method validation. The chromatographic method was validated for specificity, linearity, 
accuracy, precision, range and stability in accordance with EMA guidelines [20]. 
Selectivity. Selectivity of the method was determined by analyzing six blanks of each matrix, 
including mobile phase, heart, kidney, liver, lung or spleen obtained from healthy mice. 
Linearity and calibration range. To evaluate linearity, calibration curves were prepared and 
analyzed in triplicate, comprising three independent experiments. Data were fitted to least 
squares linear regression concerning peak area vs. concentration for ten standards prepared 
in mobile phase (2, 4, 6, 8, 10, 20, 40, 60, 80 and 100 nM) or six standards prepared in each 
biological matrix (2, 6, 10, 20, 60 and 100 nM), and by analysis of the respective response 
factors (i.e., peak area divided by concentration of each standard sample). Back calculated 
concentrations were also obtained [20]. 
Accuracy and precision. The accuracy and precision were determined by analyses of QC 
samples at three concentration levels (6, 20 and 100 n). The accuracy was expressed by 
percent of the nominal concentration value ((mean measured concentration)/(nominal 
concentration) °ø 100% and the precision by the coefficient of variation (standard deviation/ 
mean) °ø 100%). Intra-day (within-run) values were obtained by replicate analyses (n = 6) 
followed by interpolation in calibration curves prepared on the same day. Inter-day (between-
run) values were obtained from 3 independent experiments (n = 3). 
Limit of detection and quantification. The limits of detection (LOD) and quantification (LOQ) 
for each matrix were calculated as f °ø _/S, where f is 3 (LOD) or 10 (LOQ), _ is the statistics 
sy/x, and S is the slope of the calibration curve [21]. 
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Stability. The short-term stability was assessed by maintaining the QC samples at RT for 24 
h. Freeze–thaw stability of the samples was obtained over three freeze–thaw cycles, by 
thawing at RT for 2 h and refreezing for 24 h. Autosampler stability of BNIPDaoct was tested 
by analysis of QC samples, which were stored in the autosampler tray of the HPLC instrument 
for 24 h. For each concentration and each storage condition, six replicates were analyzed in 
one analytical batch. The concentration of BNIPDaoct after each storage period was 
compared to the initial concentration determined for the fresh samples, processed 
immediately after preparation. 
Recovery of BNIPDaoct from biological tissue. Extractions for the recoveries of BNIPDaoct 
from biological matrices at three QC levels were performed by spiking the organ extract 
(Section 2.4.2) in mobile phase or by spiking the organ tissue before extraction. Recovery and 
precision were determined as described in Section 2.4.3. 
EXPERIMENTAL 
Development of chromatographic method. Considering the method application to studies of 
biodistribution and pharmacokinetics, the main goal to be achieved in the development of this 
chromatographic method was low detection and quantification limits, using low sample 
volumes. Furthermore, as a high sample throughput was aimed, a monolithic column coupled 
to fluorescence detection was chosen to meet these needs.  
Moreover, the development of a simplified HPLC method with isocratic elution was aimed. 
Acetonitrile was chosen as organic component and the aqueous component was composed 
by 0.10 M acetic acid/acetate buffer, pH 4.5 and 0.010 M octanesulfonic acid in order to 
guarantee pH control (buffer) and to avoid peak tailing (sulfonate as ionic pairing agent). The 
effect of aqueous to organic ratio was investigated using 0.05 _M BNIPDaoct standard. As 
expected, when the percentage of the organic phase increases, the retention time of 
BNIPDaoct decreases. Hence, in order to attain a fast separation while maintaining good 
separation of BNIPDaoct from the void volume signal (non-retained matrix components), the 
proportion of aqueous to organic components in the mobile phase was fixed at 60:40 (v/v).  
Considering that monolithic columns can provide analyte separations using high flow rates 
with an increase of pressure that can be withstand by any HPLC system, the flow rate applied 
was studied, in order to maximize sample throughput and minimize mobile phase 
consumption. The retention time decreased to 25.7, 33.7 and 50.2% when applying 2.0, 1.5, 
and 1.0 mL min−1, compared to the value obtained for 0.5 mL min−1. Hence, a flow rate of 
1.5 mL min−1 was selected, considering that it afforded low acetonitrile consumption and a 
pressure of 2.5 MPa within the HPLC system. The run time was 6 min, with a retention time of 
3.3 min for BNIPDaoct compound. 
Method validation and application to biological samples. The validation of the analytical 
HPLC method was carried out by evaluating its selectivity, linearity, intra-day and inter-day 
precision and accuracy, stability, and extraction recovery.  
For selectivity, analyses of blank samples of all the matrices were performed as shown in Fig. 
2, where a chromatogram for 0.10 _M BNIPDaoct standard is also presented. No interference 
for BNIPDaoct detection from endogenous compounds present in tissue extracts was 
observed as no peaks at the BNIPDaoct retention time were detected (Fig. 2). Any potential 
interfering compound was washed from the column together with the solvent front, particularly 
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for liver and kidney samples.  
Regression analysis data from calibration curves in mobile phase and biological tissue 
extracts are given in Table 1. Two calibration ranges were established for BNIPDaoct: a low 
range for concentrations between 0.002 and 0.020 _M and a high range between 0.010 and 
0.100 _M. Sensitivity, assessed as the slope of the calibration curve, was 5 to 10% lower for 
the low range. Calibration curves for BNIPDaoct in mobile phase were linear and reproducible, 
with correlation coefficient >0.9996. The back calculated concentrations presented deviations 
<5.9% from the nominal value, meeting the requirements of EMA guideline [20]. The 
calculated LOD was 0.5 nM and the LOQ was 1.6 nM. 
Calibration curves for BNIPDaoct in the biological matrices tested were also linear for the two 
ranges correlation coefficients ≥0.9997 (Table 1). The LOD and LOQ for biological matrices 
were ≤0.8 and ≤1.8 nM, respectively (Table 1), corresponding to values ≤4 and ≤9 nmol g−1 in 
mice organs.  
Accuracy and precision (inter- and intra-day) were also estimated. The intra-day precision and 
accuracy were calculated by analyzing the QC of all matrices at concentrations of 0.006, 
0.020 and 0.100 _M and the 0.020 _M standard was interpolated in both calibration curves 
(Table 2). The intra-day precision was ≤1.9% and accuracy ranged between 97.3 and 106.8%. 
The inter-day precision was ≤7.2% and accuracy ranged between 96.6 and 105.6% (Table 2). 
Both intra- and inter-day precision and accuracy found have acceptable values, because 
precision for each concentration level, represented as CV, did not exceed 15% and the 
accuracy range was between 85 and 115% [20]. 
The stability of BNIPDaoct at laboratory temperature was assessed analyzing fresh samples 
and analyzing the same samples after 24 h at RT (20 °æ 2 ◦C). BNIPDaoct showed stability in 
all matrices after this period as can be seen from data in Table 3, where recoveries ranged 
from 92.6 to 105.9%, with a mean value of 100.0 °æ 2.7%. The autosampler stability was 
assessed analyzing fresh samples and analyzing the same samples after 24 h after the first 
injection. BNIPDaoct was stable in the autosampler for at least 24 h (Table 3), providing 
recovery values in all matrices between 94.1 and 103.2%, with a mean value of 99.1 °æ 2.4. 
The freeze–thaw stability of BNIPDaoct over three freeze–thaw cycles was also assessed, 
providing values of 89.1–102.5% for analyte recovery (Table 3) and a mean value of 97.1 °æ 
2.8, showing the stability during sample storage and handling, according to EMA guidelines, 
which recommend that mean concentration at each level should be within 20% of the nominal 
concentration.  
Finally, extraction efficiency was assessed, by spiking organs harvested from healthy animals 
and processing as described in Section 2.3.3 (Table 4). Recoveries were similar to all tissues 
and for both BNIPDaoct in solution (mean recovery 93.2 °æ 2.1%) and nanoencapsulated 
BNIPDaoct (mean recovery 92.3 °æ 2.4%). Therefore, recovery values are acceptable for all 
organs and suitable for reliable bioanalysis. 
Application to biodistribution assessment. The validated HPLC method was applied to 
assess the biodistribution of free and nanoencapsulated BNIPDaoct. PLGA nanoparticles 
containing BNIPDaoct presented a mean size of 156 °æ 3 nm, with a polydispersity index of 
0.08 °æ 0.03, and Zeta potential of −5.1 °æ 0.7 mV. The amount found in each organ and the 
relative distribution is given in Fig. 3. A larger amount of BNIPDaoct (3.1% of administered 
mass as free drug) was found compared to BNIPDaoct administered in nanoencapsulated 
form (1.5% of administered mass). The distribution per harvested organs was similar for both 
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formulations, with a large amount found in liver (68%), and followed by kidney (16%), spleen 
(10%), lung (5%) and heart (1%). Considering the organs were harvested 1 h after drug 
administration, a similar distribution profile was observed, with a larger amount of free drug 
recovered. Nevertheless, we would expect an increased amount of encapsulated BNIPDaoct 
if quantification was performed following a longer time (e.g., 24 h) after drug administration 
because the bio-accumulation of encapsulated BNIPDaoct requires more time due to their 
interactions with complement system and inespecific cellular interactions. 
CONCLUSIONS 
A simple, sensitive, accurate and precise HPLC method was developed and fully validated for 
determination of BNIPDaoct in biological samples. This method was convenient for the 
quantification of BNIPDaoct in mice organ samples, allowing future application to 
bioavailability assessment for longer harvest times (e.g., 12 and 24 h). Further application will 
also target pharmacokinetic studies and application of other formulations for BNIPDaoct 
delivery. Furthermore, this validated method can potentially be applied in the biodistribution of 
other mono and bisnaphthalimido molecules. 
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TABLES & FIGURES 
 
 
 
Table 1. Calibration curve parameters
a
, limit of detection (LOD) and quantification (LOQ) for BNIPDaoct in 
mobile phase and tissue extracts. 
Table 2. Accuracy and precision for the analysis of BNIPDaoct in mobile phase and tissue extracts. 
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Table 3. Stability of BNIPDaoct at different experimental conditions for all matrices tested. 
Table 4. Extraction efficiency of BNIPDaoct from mouse organs at different concentration levels. 
Figure 1. Chemical structure of bisnaphthalimidopropyldiaaminooctane (BNIPDaoct). 
Figure 2. Chromatograms of BNIPDaoct (0.10 _M, A) and blank heart (B), spleen (C), lung (D), kidney (E), and 
liver (F). Fig. 3. Amount (A). 
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Figure 3. Amount (A) and relative distribution (B) of BNIPDaoct recovered from mice organs (n = 4) after 
administration of nanoencapsulated (white bars) or free drug (grey bars). 
